Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
24.66 EUR | -0.80% | -3.60% | -33.33% |
May. 31 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
May. 31 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
Evolution of the average Target Price on Galapagos NV
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Galapagos NV
BofA Securities | |
JPMorgan Chase | |
Morgan Stanley | |
RBC Capital Markets | |
Raymond James | |
Jefferies & Co. | |
Bryan, Garnier & Co. | |
Barclays | |
Deutsche Bank Securities | |
Citigroup | |
Maxim | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- GLPG Stock
- Consensus Galapagos NV